æther THERAPEUTICS

The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older had Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program. While treatment programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. æther THERAPEUTICS' main candidate is Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: • Safer opioid pain therapy without the fear of addiction, • Cessation of opioid addiction • Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, embraces lean operations and engaged with urgency.